Cancer drug price caps called tokenistic; experts seek deeper reforms

India has capped trade margins on 137 non-scheduled anti-cancer drugs, but experts call the move a tokenistic, short-term measure. They argue patients will see little relief unless structural changes follow, including tackling pricing at the manufacturing stage and large-scale government procurement to stabilise prices. For many patients, the cost of treatment is as hard to fight as the disease.